ClinicalTrials.gg
CompletedNCT02785614Updated Sep 5, 2018

PK Study of Multi-dose Trazodone Hydrochloride Prolonged-released Tablets in Healthy Chinese

A Phase 1 interventional study of trazodone hydrochloride prolonged-release tablet and trazodone hydrochloride tablet in Depression, sponsored by Lee's Pharmaceutical Limited. Completed at 1 site in Hong Kong. Open to participants aged 19 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-09-05.

Sponsored by Lee's Pharmaceutical Limited · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
19 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 139 studies in Depression with a site in Hong Kong — 43 open to participants now, 48 under way, none of them phase 3. Depression · Hong Kong.

Enrollment
127th of 128
12 · median 91
Started
2017
with 4 others
Phase 1
2 of 139
none open now
Registered
16th of 139
by date
Lead sponsor
2 of 139
Lee's Pharmaceutical Limited

Among the 139 studies in Depression with a site in Hong Kong, this one is the 127th largest by enrollment of the 128 interventional ones that give a count, is one of 5 that started in 2017, is one of 2 in phase 1, and was the 16th registered.

Depression

8,601 studies on the registry are indexed under Depression; 1,735 are open to participants now.

Browse Depression studies →

Open to participants now

43 of the 139 studies in Depression with a site in Hong Kong are open now. Recruiting first, the newest first:

38 more — sign in →

All 43 open studies →

A study can be open while its sites in Hong Kong have not opened yet or have stopped. Only those recruiting at a site in Hong Kong →

Who these studies take

Of the 1,097 Depression studies recruiting now, 473 (43%) set no upper age limit and 523 (48%) stop at 75 or younger; 206 take children under 18; 314 take healthy volunteers.

This study: 19 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 139 studies in Depression with a site in Hong Kong, or all of them as a file.
02

Study summary

The main objective is to evaluate the pharmacokinetics comparative studies in a single dose, multiple dose

Read the detailed description

Trial II Multiple dose, the highest specification (150mg) pharmacokinetic study of Trazodone Hydrochloride Prolonged Release Tablets; 12 patients (males and females, half and half).

2-period, 2 cross (2x2) crossover design was used. screened 12 subjects (males and females) were randomly divided into two groups (II-1、II-2), each 3 males and 3 females, give the following two different crossover treatments: trazodone hydrochloride prolonged-release tablets 150 mg per day for 7 days in T group, trazodone hydrochloride tablets 50mg for 3 times per day for 7 days in R group. Wash-out period is 14 days.

Trial II. 2X2 design Group Period 1 Period 2 II -1 R T II -2 T R T group: the subjects will be provided trazodone hydrochloride prolonged-release tablet 150mg at about8:00am each day. Sampling site will be conducted in day 1, 5, 6, 7 before administration in this period, blood sampling will be conducted in 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, 8.0, 10.0, 12.0, 16.0, 24.0, 36.0, 48.0, 72.0h after administration on day 7.

R group: The subjects will receive 50mg trazodone hydrochloride tablet 50mg for 3 times after receiving standard light breakfast at 6:00am, standard meal at 14:00 and 22:00. Blood sampling will be conducted on day 1, 5, 6, 7 before first administration in this period, blood sampling will be conducted at 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0 (before the second time administration), 8.5, 9.0, 9.5, 10.0, 11.0, 12.0, 14.0, 16.0 (before the third time administration), 16.5, 17.0, 17.5, 18.0, 19.0, 20.0, 22.0, 24.0, 36.0, 48.0, 72.0h after administration on day 7.

5.0 mL venous blood from forearm venous blood was took through venous indwelling needle and transfer into the heparin tube. After plasma separation it stored in low temperature in a refrigerator.

03

Conditions studied

  • Depression

Browse trials for

04

Who can participate

Ages eligible
19 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Weight: all the subjects should be≥50 kg, within 19\~24 kg/m2
  • Blood pressure: SBP 90-140mmHg,DBP 50-90 mmHg;
  • All the subjects should understand this trial well and sign the inform consent form before participating this study;
  • Subjects should be able to communicate with investigators well and complete this study in accordance with protocol.

Exclusion criteria

Exclusion Criteria:

  • The baseline value of safety evaluation index is considered to be abnormal with clinical significance by investigators before participating the trial.
  • A positive surface antigen result;
  • A positive surface antigen result;
  • A positive test for antibody and syphilis testing;

Any of the abnormalities of ECGs examination occurs in screening period or the first day of administration:

  • With the history of using any drug which will inhibit or induce liver to metabolize drug within 1 month before the study initiation;
  • With the history of administrating any drugs (prescription medicine, over-the-counter drug and Chinese herbal medicine) within 2 week before the study initiation;
  • Past history of heart disease, cardiac failure, myocardial infarction, angina, unknown cause of arrhythmia, point swinging pattern of ventricular tachycardia, ventricular tachycardia, long syndrome or long QT syndrome and family history (with genetic proof or there were any close relatives died because of heart disease);
  • History of thyroid disease or past history of thyroid surgery;
  • History of immune system disease (such as thymus disease);
  • With surgery history within 6 months before this study initiation;
  • History of severe digestive disease (such as gallbladder disease with significant clinical significance, jaundice or susceptive jaundice, hepatocellular adenoma, hepatic cavernous hemangioma and the other liver diseases);
  • With history of gastrointestinal, liver and renal disease (no matter it has been cured or not) which will affect drug absorption and metabolism within 6 months before this study initiating
  • History of any serve cardiocerebral vascular system, respiratory system, metabolic system and nervous system diseases;
  • History of hematological system diseases, such as coagulation disorders;
  • History of tumor;
  • Subjects with hypokalemia and hypocalcemia (according to the lower limit value of the laboratory reference ranges;

Life style:

  • History of alcohol addicted within 6 months before the study
  • Smoking >1 cigarettes a day in the last 3 months prior to this study;
  • History of drug abuse and taking drugs (such as marihuana, cocaine, opium, benzodizepines, amphetamines, barbiturates, tricyclic antidepressant).
  • History of consumption of excessive tea, coffee and/or caffeinated beverage (more than 8 cups/day) within the period of 2 days before the administration and 8 days after administration.
  • History of consumption of grapefruit juice within the period of 2 days before and 8 days after administration.

Others:

  • Subjects who reject to take effective measures within the time period after inclusion to 3 months after administration;
  • Subjects with allergic constitution, including those who are allergic to the (microcrystalline cellulose, lactose, aerosil, sodium carboxymethyl starch, magnesium stearate) of this product;
  • History of participating any clinical trial within 3 months before this study, or participating the other clinical trial within the time period of inclusion to one month after the last time visit(after the last time administration);
  • History of blood donation within 3 months prior to this study, or within the time period of inclusion to one month after the last time visit (after the last time administration);
  • Subjects who have food allergy or have any special diet requirements, or who cannot follow the standard diet;
  • Subjects who, in the opinion of the investigator, should not participate in the study;

The female subjects are not eligible for inclusion in this study if she meet any of the following criteria above and below:

  • With the history of consumption of oral contraceptive within one month prior to this study;
  • History of long-acting estrogen or progesterone injection or implant within 6 months prior to this study;
  • The bearing-age female subjects who have not taken appropriate contraceptives within 2 weeks prior to this study;
  • The bearing-age female subjects and their spouse are not willing to take the following contraceptives measure, condom, copper intrauterine device within 3 months after inclusion;
  • Subjects who are in gestation period and lactation period;
  • Subjects with positive hCG test;
  • Single menstrual more than 80ml.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    II-1

    This is 2-period, 2 cross (2x2) crossover design was used. each 3 males and 3 females, give the following two different crossover treatments in the following sequence: R: trazodone hydrochloride tablets 50mg for 3 times per day for 7 days T: trazodone hydrochloride prolonged-release tablets 150 mg per day for 7 days. Wash-out period is 14 days.

    Drug: trazodone hydrochloride prolonged-release tablet · Drug: trazodone hydrochloride tablet

  • Experimental
    II-2

    This is 2-period, 2 cross (2x2) crossover design was used. each 3 males and 3 females, give the following two different crossover treatments in the following sequence: T: trazodone hydrochloride prolonged-release tablets 150 mg per day for 7 days R: trazodone hydrochloride tablets 50mg for 3 times per day for 7 days. Wash-out period is 14 days.

    Drug: trazodone hydrochloride prolonged-release tablet · Drug: trazodone hydrochloride tablet

Interventions

  • Drugtrazodone hydrochloride prolonged-release tablet

    150 mg, oral administration, 1 per day

  • 50mg, oral administration 3 times per day

06

What researchers measure

Primary outcomes

  1. Area Under Curve (AUC)

    To observe area under curve characteristics of Trazodone in single or multiple dose groups

    Time frame: day 1, 5, 6, 7 before administration and 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 8 hours, 10 hours, 12 hours, 16 hours, 20 hours, 24 hours, 36 hours, 48 hours, 72 hours after administration on day 7

07

Study locations

1 site
  • Phase I Clinical Trial Centre, Chinese University of Hong Kong
    Hong Kong, Sha Tin New Territories 000000, Hong Kong
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2017 to primary completion in Nov 2017, 6 months.

Of 102 phase 1 interventional studies under Depression, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 54. This study's 6 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2016
First posted
May 30, 2016
StartActual
May 1, 2017
Primary completionActual
Nov 30, 2017
CompletionActual
Jan 4, 2018
Last update
Sep 5, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 5, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02785614
Responsible party
Sponsor
First posted
May 30, 2016
Start date
May 1, 2017
Primary completion
Nov 30, 2017
Completion
Jan 4, 2018
Last update
Sep 5, 2018

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trazodone

Start the discussion